Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 10/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3490397 | 0.89 | GSK3B (0.66) | GSK3BNPC1RAB9AKDM4ENOTUM | |
| SCHEMBL3492891 | 0.85 | GSK3B (0.61) | GSK3BNOTUM | |
| SCHEMBL3491285 | 0.84 | GSK3B (0.55) | GSK3BNPC1RAB9AKDM4EMAPT | |
| SCHEMBL3492530 | 0.83 | GSK3B (0.54) | GSK3BNPC1RAB9AHTTKDM4E | |
| SCHEMBL3490534 | 0.83 | GSK3B (0.72) | GSK3BNPC1 | |
| Methylamine SCHEMBL3491314 | 0.83 | GSK3B (0.54) | GSK3BNPC1RAB9AKDM4ENOTUM | |
| SCHEMBL27418746 | 0.83 | RAB9A (0.64) | NPC1RAB9AHTTKDM4EMAPT | |
| SCHEMBL3491706 | 0.83 | GSK3B (0.61) | GSK3BNPC1RAB9ANOTUMSMN1; SMN2 | |
| SCHEMBL3491126 | 0.83 | GSK3B (0.53) | GSK3BNPC1RAB9AHTTKDM4E | |
| SCHEMBL3490942 | 0.81 | GSK3B (0.59) | GSK3BNPC1RAB9ANOTUMHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492378-B2 | GSK-3β inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-23 | — | — | US | disclosed |
| US-20100069381-A1 | GSK-3BETAINHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069381-A1 | GSK-3BETAINHIBITOR | GSK3B, GSK3A, GSKIP | GSK3B 1/4885NPC1 1571/4885RAB9A 3231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.